Active Cancer Brain & Nervous System
Regression Evaluation of pancreatic cancer using Single-cell sPatial multi-Omics following Neoadjuvant therapy for Survival Enhancement (RESPONSE)
About this grant
This summary is based on the grant title only — the full abstract was not available.
Research project funded by CSO at University of Glasgow.
View the original record at the funder ↗
Researchers
Nigel Jamieson (EPMC Awardee)
Related Research
Grants with similar aims, by meaning.
PAN-EX: A Pooled Analysis of Individual Clinical and Molecular Data of Two Trials of Neoadjuvant Chemotherapy in High Risk Rectal Cancer (EXPERT and EXPERT-C)
Predicting and measuring response to neoadjuvant chemotherapy through novel imaging, tissue analyses and modelling of peritumoural tissues
European Study Group for Pancreatic Cancer (ESPAC) - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic cancer.
The development of MicroRNAs as a biomarker for response to neo-adjuvant chemotherapy in patients with locally advanced Pancreatic Ductal Adenocarcinoma
PRECISION-Panc: Advancing personalised medicine treatment strategies for pancreatic cancer.
Original classification
NonePlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know